Chicago, IL (PRWEB) August 20, 2015
The Alliance for the Advancement of Cellular Therapies (AACT), an educational and informational regenerative medicine organization, will host its inaugural conference, The Dilemma of Difficult Diseases: Cell Therapy to the Rescue?, September 17-18, 2015 at The Drake Hotel in Chicago, Illinois. The Conference brings together scientists, physicians, regulatory experts, and medical professionals to discuss protocols and the process of addressing difficult diseases through evidence-based science and leading edge cellular therapies. The interactive conference will provide several disease-specific forums for discussions on bridging the gap between research and critical point of care issues such as patient safety, informed consent, and effective tracking of patient outcomes.
Keynote Speakers include Arnold Caplan, Ph.D., Professor of Biology and the Director of the Skeletal Research Center of Case Western Reserve University in Cleveland, Ohio; Mark Holterman, MD, Ph.D., Professor of Surgery and Pediatrics at the University of Illinois College of Medicine at Peoria; and Paolo Macchiarini, MD, Ph.D., a world-renowned thoracic surgeon and regenerative medicine pioneer in research and tissue engineering related to intrathoracic organs and tissues.
The Conference is especially relevant for medical professionals interested in gaining an understanding of the most current science and technological advances available for clinical applications across a variety of specialties. This event will give attendees the unique opportunity to avail themselves of an intensive clinical immersion while connecting with elite thought leaders from extensive scientific and medical backgrounds. Difficult diseases that will be addressed through presentations and interactive forums include autoimmune disease, diabetes, heart failure, Alzheimer’s, Parkinson’s, sickle cell, Alopecia Areata, orthopedic injuries and degenerative diseases, and more.
“Stem cells have the potential to provide very meaningful benefit to people with acute and chronic conditions,” said Leslie Miller, M.D., F.A.C.C, scheduled speaker and renowned cardiologist, University of South Florida, and investigator in more than eighty clinical trials for heart failure. “We have learned a great deal over the past ten years and now have multiple new sources and types of stem cells, routes of delivery, and information regarding the evaluation of repeat dosing. Stem cells are the most promising new therapy and will become an important option for patients within the next several years. This meeting will provide attendees with an in-depth look at all the advances in this rapidly moving field."